Member Info for Lionel1

Bless you Niss , sometimes it’s a bless to have a mind of 5 years old .. you are lucky :-)

Have you heard about NICE fast track approval ?? GDR is one of the first to consider in that route .. future is personalised medicine and GDR is forefront on this.. I don’t know what kind of investor you are but if you don’t want overnight returns just accumulate as many shares as you can and sit back .. trust me you will do very good on this especially at this price .. I am sorry for the investors who bought 50p upwards ..

Saint , you saying none of the products out there in the world without NICE approval :-) and all the products with NICE approvals are super duper hit ???

GDR posted same:

https://www.linkedin.com/posts/genedrive-plc_genetic-study-shows-that-common-medication-activity-7099390783534833664-685I?utm_source=share&utm_medium=member_ios

Genedrive positioned very well on stroke test front, it’s been funded by govt , data also very encouraging that it will be used in routine ..

https://www.qmul.ac.uk/media/news/2023/smd/genetic-study-shows-that-common-medication-used-to-prevent-heart-attacks-may-be-ineffective-for-majority-of-british-south-asians.html#:~:text=A%20new%20study%20by%20researchers,to%20people%20of%20European%20decent

Stroke test will change everything for GDR .. I think the sp start climbing up from October onwards until NICE guidance in Dec 2023

Lol Roger , you are unbelievable.. when was the last time somebody called you an idiot ?? Must be this morning

John, You are right .

Some posters here no idea what they are talking , Star and Rogue trying their best to spread misinformation about AIHL .you guyz have no idea how the medical device companies work and sell their stuff , all u want is overnight share price double .. this is long game and will come good . Do something else on your free time

You are right John , it’s being rolled out across UK .. Stars another turd , leave him alone ..

I think lot of people misunderstood the magnitude of the stroke test product , Genedrive do very well from here.. it is working hand in hand with NHS, Genedrive poc will be used many other PGx test , Come back here around October,I am fairly confident that one of big Pharma will take this .Read below for your peace of mind .

https://www.thermofisher.com/blog/clinical-conversations/health-benefits-and-economic-value-of-pharmacogenomics/?amp

https://www.genomicseducation.hee.nhs.uk/blog/point-of-care-genomic-testing-suggested-for-stroke-patients/

Health Economic Assessment

Apart from clinical benefits, PGx advantages go beyond the individual patient and offer economic benefits to both payers and providers. Given that the annual cost of nonoptimized medication therapy has been estimated at $528B US dollars (USD) (23), PGx may offer an opportunity to lower costs associated with actionable DGIs.

PGx can provide cost-effective health treatment

Addressing the economic impact of PGx on mental health treatment, one study estimated the saving of reduced emergency and hospitalization utilization to almost $2K USD over a 6-month follow-up (14). The positive impact of PGx-guided psychiatric drug selection on medication adherence related to a cost savings of around $560 USD over a 4-month follow-up period (16). For polypharmacy patients, PGx savings were estimated in the range of $4K USD per patient (21).

Roger , Lol you still here.. I think we need a pressure wash to get rid of you ..

Https://www.sagentiainnovation.com/wp-content/uploads/2020/10/SI-CS-M-D-Genedrive-21.pdf

Sagentia doing all the manufacturing for Genedrive.

Roger and Starr , I am not sure what you both doin here if you are not invested , you both are like turd never flushed away .. Rogue , don’t you have any family or friends , sometimes you vomit your rubbish here in the middle of a night :-) , seek some professional help .. I sincerely wish for your recovery, get well soon, ofcource starrs u too

Very odd price action, something doesn't look right...

Agree, NHS moving towards GDx for cost saving and Genedrive will play a key role.

Some people are always here to shoot down whoever posts some positive news, I don't understand what they get with this nonsense .

Thank you MyIPA, I have started reading the forum from last week or so .. I have spotted 2 clueless posters, Roguer65 and somebody called Starres*** , they keep saying they are not invested but they are here full time bashing the stock, and also split personalities :-)

I believe this will be taken over eventually by a bigger player, Tons of data available online what the company is doing but some people crying and blaming the company..

Leveraging partnerships to realise the UK’s potential in genomics:

Pharmacogenomic treatment optimisation can also significantly alleviate pressure on the NHS, both on staff

time and economically. Ensuring patients receive effective treatment could deliver sizeable cost savings. The UK spends at least £16.8 billion on prescription drugs per year; improving the effectiveness of these prescriptions would deliver significant efficiency improvements.67 Furthermore, ensuring maximal safety is not only beneficial for patients but has great economic value – 8,000 UK hospital beds are occupied by patients suffering from ADRs at any one time, at a cost of £1.6 billion per year.68

Driving value for the healthcare system through providing versatile data

As well as providing value for HCPs and the NHS, GDx provide value to the wider healthcare system, including to payers. The fundamental nature of genomic data confers versatility in its application, meaning that the data delivered by GDx can inform clinical decisions over a patient’s lifetime, maximising cost-effectiveness for payers.

• Where the variant of a particular gene has implications for multiple facets of healthcare, data about this gene can be highly valuable.70 For example, the enzyme encoded by the CYP2C19 gene metabolises at least 10% of drugs and prodrugs currently in clinical use, including blood thinners, anxiolytic drugs and anti-seizure drugs.71 Different variants of the gene encode enzymes of increased or decreased activity, meaning the dose of the drug might have to be altered to have the same physiological effect in different patients.72,73 Novel diagnostics can deliver CYP2C19 variant results from a cheek swab in as little as one hour,74 generating data that can influence many prescription decisions throughout the lifetime of the patient.

Good luck for the people who Genuinely invested.

Youtube.com/watch?v=FjWpZiy8zS0&t=57s

NHS is going to work with Genedrive on multiple projects.. Great video.

[LINK REMOVED]